Consolidated Statements of Comprehensive Loss-Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Net product revenue	$ 0	$ 6,542	$ 0	$ 23,404
Collaborative agreements	0	0	0	33
Royalties and other revenue	23	92	284	359
Total revenues	23	6,634	284	23,796
Operating expenses:
Cost of sales (including finite-lived intangible asset amortization)	0	633	0	1,929
Research and development, including stock-based compensation of $1,138, $1,029, $3,608 and $5,154, respectively	15,682	40,147	38,548	152,629
Selling, general and administrative, including stock-based compensation of $1,574, $875, $4,741 and $5,440, respectively	7,303	11,997	23,496	40,798
Asset Impairment Charges	0	0	0	1,600
Total operating expenses	22,985	52,777	62,044	196,956
Gain on sale of non-financial assets	0	132,818	0	132,818
Loss from operations	(22,962)	86,675	(61,760)	(40,342)
Gain (Loss) on Extinguishment of Debt	0	(255)	0	(255)
Interest expense	(171)	(4,118)	(507)	(14,374)
Interest and other income, net	11	301	120	1,892
Net loss	$ (23,122)	$ 82,603	$ (62,147)	$ (53,079)
Net income (loss) per common share, Basic	$ (0.16)	$ 0.77	$ (0.43)	$ (0.50)
Earnings Per Share, Diluted	$ (0.16)	$ 0.71	$ (0.43)	$ (0.50)
Shares used in computing net loss per common share, Basic	145,820	107,309	144,558	106,974
Weighted Average Number of Shares Outstanding, Diluted	145,820	117,552	144,558	106,974
Unrealized gain on investments	$ 0	$ (277)	$ 1	$ (49)
Comprehensive loss	(23,122)	82,326	(62,146)	(53,128)
Supplemental Income Statement Elements [Abstract]
Stock-based compensation expense associated with selling, general and administrative expense	1,574	875	4,741	5,440
Stock-based compensation expense associated with research and development expense	$ 1,138	$ 1,029	$ 3,608	$ 5,154